KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Net Margin (2018 - 2025)

Amneal Pharmaceuticals has reported Net Margin over the past 8 years, most recently at 6.09% for Q4 2025.

  • Quarterly results put Net Margin at 6.09% for Q4 2025, up 893.0% from a year ago — trailing twelve months through Dec 2025 was 4.24% (up 688.0% YoY), and the annual figure for FY2025 was 4.24%, up 842.0%.
  • Net Margin for Q4 2025 was 6.09% at Amneal Pharmaceuticals, up from 2.31% in the prior quarter.
  • Over the last five years, Net Margin for AMRX hit a ceiling of 6.09% in Q4 2025 and a floor of 21.6% in Q2 2022.
  • Median Net Margin over the past 5 years was 0.46% (2021), compared with a mean of 1.46%.
  • Biggest five-year swings in Net Margin: plummeted -2431bps in 2022 and later skyrocketed 2359bps in 2023.
  • Amneal Pharmaceuticals' Net Margin stood at 1.19% in 2021, then surged by 40bps to 0.71% in 2022, then crashed by -2150bps to 15.99% in 2023, then soared by 82bps to 2.84% in 2024, then surged by 314bps to 6.09% in 2025.
  • The last three reported values for Net Margin were 6.09% (Q4 2025), 2.31% (Q3 2025), and 4.92% (Q2 2025) per Business Quant data.